A Novel Diagnostic Assay for Platelet-Type von Willebrand Disease Público
Su, Ally (Spring 2022)
Abstract
Platelet-type von Willebrand disease (PT-VWD) is rare and often misdiagnosed due to its phenotypically similar symptoms with type 2B VWD. Both subtypes possess gain-of-function mutations that increase the affinity between the von Willebrand factor (VWF) and the glycoprotein Ib⍺ of the platelets. For PT-VWD, this mutation occurs on GPIb⍺. For type 2B VWD, it develops on VWF. The current diagnosis utilizes ristocetin-induced platelet aggregation mixed studies and genetic sequencing, which are unstandardized and expensive. This study established a cell-based model for PT-VWD to circumvent obtaining patient plasma samples and developed a flow cytometry assay to identify PT-VWD. A stable cell line expressing mutated GPIb⍺ (W230L) was generated through transfection and maintained with hygromycin. GPIb⍺(W230L) bound to full-length VWF and monomeric A1 at a higher affinity than GPIb⍺ WT, as observed in flow cytometry. The binding difference between GPIb⍺ (W230L) and GPIb⍺ WT was amplified in a dose-dependent manner when incubated with activators such as botrocetin and 1D12. Utilizing truncated A1 (NAIM-A1) or diluting plasma at a 1:1 ratio also heightened the binding difference between GPIb⍺ (W230L) and GPIb⍺ WT. By employing these parameters to maximize the binding of GPIb⍺ (W230L), it becomes possible to identify PT-VWD and diagnose patients via a rapid and accessible assay.
Table of Contents
Table of Contents
Chapter 1. An Introduction to von Willebrand Disease and von Willebrand Factor 1
1.1. An Overview 2
1.2. von Willebrand Disease 2
1.3. Glycoprotein Ib-IX 3
1.4. Platelet-Type von Willebrand Disease 3
1.4.1. Ristocetin-Induced Platelet Aggregation Mixed Studies 4
1.4.2. Genetic Testing 5
1.4.3. Issues 5
2. kk
Chapter 2. Materials and Methods 6
2.1. Experimental Overview 7
2.2. Establishment of a Stable Cell Line 7
2.2.1. The Plasmid 7
2.2.2. Restriction Digestion 7
2.2.3. Cell Culture 8
2.2.4. Transfection 9
2.2.5. Cell Lysis 9
2.2.6. Western Blot 9
2.2.7. Cell Sorting 10
2.3. Flow Cytometry 10
2.3.1. Expression of GPIbβ and GPIX 11
2.3.2. GPIb⍺ Binding to Full-length VWF 11
2.4. Activators 11
2.5. Data analysis on FlowJo 12
3. Results
Chapter 3. Results 13
3.1. Establishment of a Stable Cell Line 14
3.1.1. Confirming the plasmid with Restriction Digestion 14
3.1.2. Visualizing GFP in CHO cells 14
3.1.3. Checking the Success of the Transient transfection of GPIb⍺ 15
3.1.4. Flow cytometry 16
3.2. Higher Binding affinity of GPIb⍺ 17
3.3. Optimizing the conditions 17
3.3.1. GPIb⍺ (W230L) Responds Dose-Dependently to Botrocetin 18
3.3.2. GPIb⍺ (W230L) Exhibits Higher Binding to NAIM-A1 (1238-1461) 19
3.3.3. Determining the Ideal Plasma Concentration at a 1:1 Dilution 20
3.3.4. 1D12 is a Great Activator
4. Discussion
Chapter 4. Discussion 21
4.1. Optimizing the Use of Streptavidin-Conjugated Violet Fluorophore Beads 22
4.2. Further Studies with Ristocetin 24
4.3. The Declining Homogenity of the CHO cell line 24
4.4. Conclusion 25
References 26
Figure 1 8
Figure 2 12
Figure 3 15
Figure 4 17
Figure 5 18
Figure 6 19
Figure 7 23
About this Honors Thesis
- Permission granted by the author to include this thesis or dissertation in this repository. All rights reserved by the author. Please contact the author for information regarding the reproduction and use of this thesis or dissertation.
School | |
---|---|
Department | |
Degree | |
Submission | |
Language |
|
Research Field | |
Palavra-chave | |
Committee Chair / Thesis Advisor | |
Committee Members |
Primary PDF
Thumbnail | Title | Date Uploaded | Actions |
---|---|---|---|
|
A Novel Diagnostic Assay for Platelet-Type von Willebrand Disease () | 2022-05-04 10:59:00 -0400 |
|
Supplemental Files
Thumbnail | Title | Date Uploaded | Actions |
---|